DEFA14A: Enhabit Urges Stockholders to Reject AREX's Director Nominees, Citing Lack of Experience and Destabilizing Transformation Committee

Enhabit is urging stockholders to vote for its director nominees at the upcoming 2024 Annual Meeting, arguing that AREX Capital Management's proposed board members lack relevant experience and their transformation committee would be disruptive.

Summary

• Enhabit is urging stockholders to vote for its director nominees at the upcoming 2024 Annual Meeting of Stockholders scheduled for July 25, 2024.
• AREX Capital Management is attempting to replace nearly all of Enhabit's independent directors with its own nominees.
• Enhabit argues that AREX's nominees lack the necessary experience in key areas such as payors, hospital networks, and labor management.
• Enhabit claims that AREX's proposed Transformation Committee would act as a shadow management team and destabilize the company.
• Enhabit criticizes AREX's understanding of the business and industry, citing inaccurate claims about payor mix and overhead costs.
• Enhabit believes that giving AREX control of the board would be value-destructive and reckless.
• Enhabit's Board of Directors recommends stockholders vote FOR Enhabit's nine highly qualified nominees on the YELLOW proxy card.

Sentiment

Score: 4

Explanation: The document has a negative sentiment due to the ongoing proxy fight and the company's concerns about AREX's nominees and proposed changes. While Enhabit highlights some positive aspects of its business, the overall tone is defensive and critical of AREX.

Positives

• Enhabit's board has been almost wholly refreshed since its separation from Encompass Health Corporation two years ago.
• The company states that its performance over the last two quarters indicates that the business has stabilized and is positioned for profitable growth.
• Enhabit has successfully eliminated high-cost contract labor in both its Home Health and Hospice segments.
• Enhabit has focused on the buildout of the IT organization to enhance its analytics capabilities and automate processes.

Negatives

• AREX Capital Management is attempting to take control of Enhabit's Board of Directors.
• Enhabit claims that AREX's nominees lack the necessary experience in key areas such as payors, hospital networks, and labor management.
• Enhabit criticizes AREX's understanding of the business and industry, citing inaccurate claims about payor mix and overhead costs.
• AREX's proposed Transformation Committee would act as a shadow management team and destabilize the company.

Risks

• The potential for destabilization and disruption if AREX's nominees are elected and the Transformation Committee is formed.
• The risk that AREX's nominees lack the necessary expertise to effectively oversee Enhabit's business.
• The risk that AREX's proposed changes could negatively impact Enhabit's strategy and performance.
• The risk of potential conflicts of interest with Dr. Sheff having a role on the Board while the Company is actively suing Vistria for substantial damages and Vistria is heavily invested in the success of a competing entity.

Future Outlook

Enhabit aims to continue executing its strategy and enhancing value for all stockholders, with the current board overseeing this process.

Management Comments

• Enhabit's Board was intentionally designed to have the right mix of expertise to understand the key drivers of the business.
• Our CEO has serious concerns about continuing to serve under this Transformation Committee as proposed by AREX.
• Shifting course now and handing control of the Board to AREX and its less experienced nominees so they can learn our business on the job would be value-destructive and reckless.

Industry Context

The document highlights the importance of diverse board experience in the home health and hospice industry, noting that Enhabit's peer companies typically have only one independent director with direct operating experience in the sector.

Comparison to Industry Standards

• The document references Amedisys, Inc. and The Pennant Group, Inc. as Enhabit's peer group as identified by AREX.
• It notes that boards of these companies are comprised of directors who have a diverse range of senior-level skills and experiences adjacent to home health and hospice, in line with the approach of the Enhabit Board.
• The document claims that at each of these companies, it appears that only one independent director has direct operating experience within the home health and hospice industry.

Legal Proceedings

• Enhabit and Encompass have litigation in the Delaware Court of Chancery against Vistria Group, a private equity firm which funded the formation of an Enhabit competitor (VitalCaring) by our founder and former CEO.

Stakeholder Impact

• The outcome of the proxy fight will impact shareholders, as it will determine the direction and oversight of the company.
• Employees could be affected by potential changes in strategy and operations if AREX's nominees are elected.
• Patients and their families could be impacted by changes in the quality and delivery of care.

Next Steps

• Stockholders are urged to vote on the YELLOW proxy card for Enhabit's nominees.
• The outcome of the vote at the 2024 Annual Meeting will determine the composition of Enhabit's Board of Directors.

Key Dates

Keywords

Enhabit, AREX Capital Management, proxy fight, board of directors, director nominees, stockholders, home health, hospice, annual meeting, corporate governance